MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Russian Bear who wrote (1103)	8/26/1998 2:01:00 PM
From: seminole	Read Replies (1) of 1826

Bear I have not looked at the data closely yet but a few things jumped out at me. Also you can use this link to compare drugs and compare drugs with a known mechanism of action (COMPARE). Look at Leukemia line, RPMI-8226, see how high the concentration needs to be (E-4M). This cell line does not have active transport and higher diffussional controlled concentrations are needed. Lets hope normal cells in humans fail to take up the drug like this cell line. 1) I don't know but maybe it still needs to be entered. 2) I not sure I can translate but the GI50 units are moles per liter not moles. Moles per liter can be converted into weight per volume useing the molecular weight (247 grams/mole). 3) I have no information on the NCI lines. The DU-145 lines was studied in mice and referenced in the press release on the start of Phase II trials. It is a carcinoma, prostate that metastasised to the subjects brain before being isolated. The cell line has no detectable hormone sensitivity. Has anyone noticed the freefall of ENMD? good luck hunting bags

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next